These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 5503943)

  • 1. Urokinase-induced fibrinolysis of 125-I-fibrin. Conditions for first-order activation kinetics, density-gradient separation of split products, and a microassay.
    Ball AP; Day ED
    Thromb Diath Haemorrh; 1970 Dec; 24(3):463-74. PubMed ID: 5503943
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasminogen-fibrinogen complex formation as a prelude to fibrinogenolysis. A density-gradient ultracentrifugation study of radioiodinated systems involving urokinase, plasminogen, and fibrinogen.
    Ball AP; Silver D; Day ED
    Thromb Diath Haemorrh; 1971; 25(1):114-28. PubMed ID: 5103731
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro potentiation of urokinase-activated lysis of human fibrin clots.
    Singh K; Vézina C
    J Med; 1974; 5(6):297-302. PubMed ID: 4528600
    [No Abstract]   [Full Text] [Related]  

  • 4. Fibrinolytic activation of plasma by means of urokinase in vitro and in vivo.
    Nanninga LB; Guest MM
    Thromb Diath Haemorrh; 1970 Oct; 24(1):33-42. PubMed ID: 5483972
    [No Abstract]   [Full Text] [Related]  

  • 5. Prothrombin converting-and fibrinolytic effects of ecarin.
    Kornalík F
    Czech Med; 1985; 8(1):51-4. PubMed ID: 3922719
    [No Abstract]   [Full Text] [Related]  

  • 6. Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin.
    Camiolo SM; Thorsen S; Astrup T
    Proc Soc Exp Biol Med; 1971 Oct; 138(1):277-80. PubMed ID: 5125527
    [No Abstract]   [Full Text] [Related]  

  • 7. Differences in the binding to fibrin of urokinase and tissue plasminogen activator.
    Thorsen S; Glas-Greenwalt P; Astrup T
    Thromb Diath Haemorrh; 1972 Aug; 28(1):65-74. PubMed ID: 4672651
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substrate composition and the effect of epsilon-aminocaproic acid on tissue plasminogen activator and urokinase-induced fibrinolysis.
    Thorsen S; Astrup T
    Thromb Diath Haemorrh; 1974 Dec; 32(2-3):306-24. PubMed ID: 4281113
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibrinolytic activity in healing wound.
    Peterson HI; Peterson A; Zederfeldt B
    Acta Chir Scand; 1969; 135(8):649-52. PubMed ID: 5368949
    [No Abstract]   [Full Text] [Related]  

  • 11. [Late results following fibrinolysis therapy of venous thromboses].
    Breddin HK
    Internist (Berl); 1984 Feb; 25(2):102-7. PubMed ID: 6368451
    [No Abstract]   [Full Text] [Related]  

  • 12. Experimental and clinical studies on the thrombin-like enzyme from the venom of Bothrops atrox. On the primary structure of fragment E.
    Egberg N
    Acta Physiol Scand Suppl; 1973; 400():1-47. PubMed ID: 4599946
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effects of heparin on plasmin and plasminogen activation].
    Manmi S
    Nihon Ketsueki Gakkai Zasshi; 1971 Oct; 34(5):591-4. PubMed ID: 4261759
    [No Abstract]   [Full Text] [Related]  

  • 14. A method to correct for the continuing activation during the second stage in a two-stage assay. Exemplified by urokinase activation of plasminogen determined by the lysis time method.
    Berg W
    Thromb Diath Haemorrh; 1968 Mar; 19(1):161-8. PubMed ID: 4231459
    [No Abstract]   [Full Text] [Related]  

  • 15. [Plasmin formation in a fibrin network].
    Kotschy M; Knapik M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1971; 95(2):167-73. PubMed ID: 4106005
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies on the thrombin clotting time. II. The influence of fibrin degradation products.
    Arnesen H
    Scand J Haematol; 1973; 10(4):291-7. PubMed ID: 4764611
    [No Abstract]   [Full Text] [Related]  

  • 17. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of defibrinating agents ancrod and reptilase in the treatment of thromboembolism.
    Kwaan HC
    Thromb Diath Haemorrh Suppl; 1973; 56():239-51. PubMed ID: 4617331
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmacological potentials for activating the fibrinolytic system].
    Markwardt F
    Z Gesamte Inn Med; 1984 May; 39(10):209-13. PubMed ID: 6380126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen assay by means of the lysis time method.
    Berg W; Korsan-Bengtsen K; Ygge J
    Thromb Diath Haemorrh; 1965 Sep; 14(1-2):127-44. PubMed ID: 16955971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.